CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 48,995 enrolled
Drug / intervention
Freenome testother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04369053
NCT04369053N/ACompleted
CompareCT.gov

Prevention of Colorectal Cancer Through Multiomics Blood Testing

Freenome Holdings Inc.·observational·Posted Apr 30, 2020·Updated Dec 26, 2025

In Brief

An observational study evaluating Freenome test for Colon Cancer and 10 related conditions. Completed, enrolled 48,995 participants across 148 sites in 2 countries.

Detailed Summary

The PREEMPT CRC study is a prospective multi-center observational study to validate a blood-based test for the early detection of colorectal cancer by collecting blood samples from average-risk participants who will undergo a routine screening colonoscopy.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsColon Cancer, Rectal Cancer, Colon Neoplasm, Colon Diseases, Colon Lesion, Colon Polyp, Colorectal Cancer, Polyp, Adenoma, Rectal Diseases, Gastrointestinal Tract Cancers
CountriesCanada, United States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedApr 30, 2020
Enrollment StartMay 20, 2020
Primary CompletionFeb 29, 2024
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 6.2 years ago

Interventions

Freenome testother

Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled. Participants will undergo blood collection and will then complete a standard-of-care screening colonoscopy.